Ligand Pharmaceuticals (LGND) Proxy Filing summary

Voting matters and shareholder proposals

• Proposal No. 4 seeks approval to amend and restate the 2002 Stock Incentive Plan, increasing shares available for issuance by 1.3 million, raising total equity overhang to 28.1%.

• Subtracting shares held by former employees reduces the overhang to 22.7%, below the ISS-recommended cap.

• Internal analysis details the breakdown of options, RSUs/PSUs, and shares available under combined and inducement plans.

Executive compensation and say-on-pay

• Equity compensation is emphasized as a key tool for attracting and retaining top talent, aligning employee and shareholder interests.

• The company relies on equity incentives to motivate executives and private equity professionals amid competitive opportunities.

Board of directors and corporate governance

• The company highlights the impact of recent restructuring and spin-out transactions, which reduced headcount from nearly 175 to below 40, lowering ongoing cash and equity expenses.

• Adjusted earnings have more than doubled since these transactions, benefiting shareholders.